Today’s post will be a little admonishment of you, my loyal readers. So, please be open-minded and think about what I have to say to you. A number of months ago I mentioned the new prostate cancer research-funding project we have embarked upon, Start A Cure (www.StartACure.com). For those of you who might have missed [...]
A post from Alan on the Advanced Prostate Cancer On-Line Support Group shared a link, which should interest all of us. It should interest us all because it will have an effect on each and every one of us, whether we are a prostate cancer survivor, if we become one in the future. Actually the [...]
We have many new drugs that have been recently approved to treat advanced prostate cancer. Two of these drugs are abiraterone (Zytiga) and enzalutamide (Xtandi). These drugs offer new hope to men with advanced prostate cancer after the cancer has become resistant to hormone therapies (called "castration-resistant prostate cancer"). These drugs are a real breakthrough, [...]
Researchers at Johns Hopkins has concluded that metastasis-free survival appeared to independently predictor of overall survival (OS) in men with recurrent prostate cancer who underwent androgen deprivation therapy (ADT) after developing metastases. Men with biochemically recurrent prostate cancer (PSA only) tend to survive for long periods so the FDA gold standard for clinical trial endpoint [...]
A study from Michael T. Schweizer, MD, and colleagues at Johns Hopkins University in Baltimore Md. concluded that the longer the metastasis-free survival after a radical prostatectomy the longer overall survival in men who experience biochemical recurrence (PSA only recurrence) of their prostate cancer. This conclusion was made from a retrospectively study of 450 men [...]
Although there are now many new treatments for advanced prostate cancer, hormone therapy (ADT) has remained the standard of care for the last 70 years. While hormone therapy can provide pain relief, it is never curative. Long-term hormone therapy produces decreased quality of life. Men treated with hormone therapy have weight gain, experience impotence, decreased [...]
The US Senate Appropriations Subcommittee on Defense yesterday marked-up their version of the FY14 Defense Appropriations Act. The full committee is scheduled to mark up tomorrow Thursday). The following is an excerpt from the committee’s summary of the bill: Significant increases to DoD medical research efforts, including: o $200 million for the Peer-Reviewed Medical Research [...]
All of us on androgen deprivation therapy (ADT) know that without testosterone our bodies change and we will develop insulin resistance, the precursor to diabetes. In a just very small, just published study investigators examined if endurance training would improve insulin sensitivity and body composition in men being treated with ADT for their advanced prostate [...]
Researchers at Duke University observed a survival benefit for men who had salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in the men who experience a rapid rises in PSA doubling time (DT,< 6 months). They then asked whether such a benefit also exits in men with a protracted PSA [...]
The treatment of advanced prostate cancer, and in particular castrate resistant prostate cancer (CRPC), has changed greatly over the last 4 years. Treatment options have expanded and now offer multiple treatment possibilities that did not exist 4 years ago. With the addition of all these new options, so comes the addition of significant economic costs, [...]
